📊 IART Key Takeaways
Is IART a Good Investment? Thesis Analysis
Integra LifeSciences faces severe operational distress with a $493.4M operating loss on $1.6B revenue (-30% operating margin) and negative free cash flow of -$31.1M despite positive operating cash flow, indicating significant one-time charges or fundamental business deterioration. The combination of negative FCF, inability to cover interest payments from operations (-36.2x), minimal revenue growth (1.5%), and shareholder value destruction (ROE: -49.5%) indicates serious turnaround challenges with unclear recovery timeline.
Why Buy IART? Key Strengths
- Healthy gross margin of 52% suggests underlying product economics remain viable
- Positive operating cash flow of $50.4M despite net losses shows some cash generation ability
- Adequate liquidity with current ratio of 2.54x and $235M cash position provides near-term runway
IART Investment Risks to Consider
- Massive operating loss of -$493.4M indicating severe operational dysfunction or major impairment charges
- Negative free cash flow of -$31.1M is unsustainable and will deplete cash reserves within 7-8 years at current burn rate
- Interest coverage ratio of -36.2x means company cannot cover debt service from operations, creating default risk
- Anemic revenue growth of 1.5% suggests market share losses or stagnant core business
- Significant unexplained gap between OCF and net income suggests major one-time charges that may recur
Key Metrics to Watch
- Operating margin trajectory - critical to understand nature of $493M loss and path to profitability
- Free cash flow stabilization - must return to positive before cash reserves deplete
- Revenue growth acceleration - 1.5% growth insufficient for recovery narrative
IART Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 2.54x current ratio provides a solid financial cushion.
IART Profitability Ratios
IART vs Healthcare Sector
How INTEGRA LIFESCIENCES HOLDINGS CORP compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is IART Overvalued or Undervalued?
Based on fundamental analysis, INTEGRA LIFESCIENCES HOLDINGS CORP shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
IART Balance Sheet & Liquidity
IART 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: INTEGRA LIFESCIENCES HOLDINGS CORP's revenue has shown modest growth of 6% over the 5-year period. The most recent EPS of $0.84 reflects profitable operations.
IART Growth Metrics (YoY)
IART Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $380.8M | -$3.3M | $-0.07 |
| Q2 2025 | $415.6M | -$3.3M | $-0.16 |
| Q1 2025 | $368.9M | -$3.3M | $-0.04 |
| Q3 2024 | $380.8M | -$3.3M | $-0.14 |
| Q2 2024 | $381.3M | -$3.3M | $0.05 |
| Q1 2024 | $368.9M | -$3.3M | $-0.04 |
| Q3 2023 | $382.4M | $4.2M | $0.24 |
| Q2 2023 | $381.3M | $4.2M | $0.05 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
IART Capital Allocation
IART SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for INTEGRA LIFESCIENCES HOLDINGS CORP (CIK: 0000917520)
📋 Recent SEC Filings
❓ Frequently Asked Questions about IART
What is the AI rating for IART?
INTEGRA LIFESCIENCES HOLDINGS CORP (IART) has an AI rating of STRONG SELL with 82% confidence, based on fundamental analysis of SEC EDGAR filings.
What are IART's key strengths?
Claude: Healthy gross margin of 52% suggests underlying product economics remain viable. Positive operating cash flow of $50.4M despite net losses shows some cash generation ability.
What are the risks of investing in IART?
Claude: Massive operating loss of -$493.4M indicating severe operational dysfunction or major impairment charges. Negative free cash flow of -$31.1M is unsustainable and will deplete cash reserves within 7-8 years at current burn rate.
What is IART's revenue and growth?
INTEGRA LIFESCIENCES HOLDINGS CORP reported revenue of $1.6B.
Does IART pay dividends?
INTEGRA LIFESCIENCES HOLDINGS CORP does not currently pay dividends.
Where can I find IART SEC filings?
Official SEC filings for INTEGRA LIFESCIENCES HOLDINGS CORP (CIK: 0000917520) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is IART's EPS?
INTEGRA LIFESCIENCES HOLDINGS CORP has a diluted EPS of $-6.74.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is IART a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, INTEGRA LIFESCIENCES HOLDINGS CORP has a STRONG SELL rating with 82% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is IART stock overvalued or undervalued?
Valuation metrics for IART: ROE of -49.5% (sector avg: 15%), net margin of -31.6% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy IART stock in 2026?
Our dual AI analysis gives INTEGRA LIFESCIENCES HOLDINGS CORP a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is IART's free cash flow?
INTEGRA LIFESCIENCES HOLDINGS CORP's operating cash flow is $50.4M, with capital expenditures of $81.4M. FCF margin is -1.9%.
How does IART compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -31.6% (avg: 12%), ROE -49.5% (avg: 15%), current ratio 2.54 (avg: 2).